Last updated on July 2019

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Naïve Adult Patients with Generalized Myasthenia Gravis IND 140,115 STUDY NUMBER: ALXN1210-MG-306

Other Details:

There are no medical benefits that can be guaranteed to the patient for the patient’s taking part in this research study. The patient’s willingness to take part, however, may help doctors better understand and/or treat others who have the patient’s condition. Information gained from this study may benefit others. No guarantees have been made to the patient as to the results of this research study.

Find a site near you

Start Over

Baptist Health Lexington Clinical Research Center

1740 Nicholasville Road Lexington, KY United States
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.